Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity

The clinical benefit of MAPK pathway inhibition in BRAF-mutant melanoma patients is limited by the development of acquired resistance. Using drug-naïve cell lines derived from tumor specimens, we established a preclinical model of melanoma resistance to vemurafenib or trametinib to provide insight i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartman, Mariusz L., Sztiller-Sikorska, Malgorzata, Gajos-Michniewicz, Anna, Czyz, Malgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017165/
https://www.ncbi.nlm.nih.gov/pubmed/31936151
http://dx.doi.org/10.3390/cells9010142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017165/
https://www.ncbi.nlm.nih.gov/pubmed/31936151
http://dx.doi.org/10.3390/cells9010142

Ejemplares similares